FluMist works just like a regular vaccine ... (Caregivers can administer the spray for children.) AstraZeneca expects to have doses ready for the fall-2025 flu season. By Ashley Mateo By Chris ...

AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...

FluMist is an efficacious and safely tolerated intranasal influenza vaccine. FluMist has gained approval from the FDA for self-administration by patients aged 18-49. FluMist is the first influenza ...

About AstraZeneca plc (ADR) and Merck & Co Inc AstraZeneca PLC ... Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for ...

AstraZeneca PLC, a biopharmaceutical company ... Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare ...

The FDA has approved FluMist (AstraZeneca) for self-administration by adults up to age 49 years or for caregiver administration for children aged 2 to 17 years, making it the first self ...

Q2 2025 Earnings Conference Call October 31, 2024 2:30 AM ET. Company Participants. Hiroyuki Okuzawa - Representative Director, Presi ...

In September, AstraZeneca's subsidiary MedImmune gained approval for a live H1N1 Flumist vaccine. Further afield, Beijing-based Sinovac Biotech also received approval for an H1N1 vaccine from the ...

AstraZeneca reaffirmed its commitment to combating infectious ... In addition, vaccine effectiveness data on FluMist, the only self-administered flu vaccine approved in the US, will be presented. Real ...